Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02932579 · ClinicalTrials.gov registry record · Phase 4
Utility of Pharmacogenomic Testing and Postoperative Dental Pain Outcomes
A Phase 4 study, sponsored by University of Rochester.
- Terminated
- Registry status
- Phase 4
- Development phase
- 59
- Enrollment target
NCT02932579 is a Phase 4 study that was terminated before completion, run by University of Rochester. The registered enrollment target is 59 participants.
The verdict
NCT02932579, a Phase 4 study, was terminated before completion, sponsored by University of Rochester.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 59 participants
- Enrollment target
Study Summary
Opioid analgesics are the most common postoperative pain medications used among dentists in the United States.Although these medications are highly effective in the postoperative dental pain management, not all patients optimally benefit from this therapy. Many suffer adverse consequences such as nausea, emesis, and psychomotor impairment, and there is a high prevalence of opioid prescription misuse among substance abusers within the dental patient population. The use of non-opioid analgesics including ibuprofen and acetaminophen in the management of postoperative dental pain has demonstrated equivalent or superior analgesic effects compared to opioid analgesic therapies, typically with significantly less adverse effects.However, despite these results, dentists have encountered a high variability in the success of non-opioid analgesic responses among the postoperative dental pain population.Thus, new strategies for earlier recognition of analgesic responses for pain medications is fundamental in the field of dentistry. Therefore, this study will evaluate the clinical utility of pharmacogenomic testing in acute postoperative dental pain management among healthy adults who undergo extraction of impacted mandibular third molar.
Interventions
- DRUG Ibuprofen
- DRUG acetominophen
- OTHER Pharmacogenomic Testing
- DRUG hydroxycontin/acetominophen
- DRUG Oxycontin/acetominophen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2017-07-01 |
| Est. Completion | 2021-01-13 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02932579
The ClinicalTrials.gov registry entry for NCT02932579 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ibuprofen is the first listed.
NCT02932579 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02932579 about?
NCT02932579 is a clinical study titled "Utility of Pharmacogenomic Testing and Postoperative Dental Pain Outcomes". Opioid analgesics are the most common postoperative pain medications used among dentists in the United States.Although these medications are highly effective in the postoperative dental pain management, not all patients optimally benefit from this therapy. Many suffer adverse consequences such as na...
What is the current status of trial NCT02932579?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 59 participants. The study started on 2017-07-01. Estimated completion is 2021-01-13.
What interventions are being tested in trial NCT02932579?
The interventions under investigation include: Ibuprofen (DRUG), acetominophen (DRUG), Pharmacogenomic Testing (OTHER), hydroxycontin/acetominophen (DRUG), Oxycontin/acetominophen (DRUG).
Who is sponsoring clinical trial NCT02932579?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.